Inhibition of MR signaling with MR antagonists has previously shown clinical efficacy in Duchenne muscular dystrophy (DMD) cardiomyopathy and preclinical efficacy in skeletal muscle in DMD models. Here, NR3C2 is linked to Duchenne muscular dystrophy.